Medexus Pharmaceuticals Inc (MDP.TO) has surged by over 5% in the latest trading session, driven by positive momentum in its fiscal performance.
In the latest trading session, Medexus Pharmaceuticals Inc experienced a notable increase of 5.12%, closing at CA$4.72. This rise comes amid the company's ongoing efforts to strengthen its market presence and leverage its product pipeline, particularly GRAFAPEX (treosulfan) for Injection.
Investor takeaway: Investors should consider Medexus's recent fiscal results and strategic moves as signs of potential growth, especially with the company's focus on innovative therapies and market expansion.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeMarket cap
$161.47M
52W high
$5.25
52W low
$2.47
1W change
+0.59%
Beta
1.81
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 33.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.81
+33.5% Upside
Current Price
C$5.10
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
52.5%
Annualized
90-Day Vol
43.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$6.10
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.41 | C$4.52 – C$6.49 |
| 60 trading days | C$5.74 | C$4.45 – C$7.42 |
| 90 trading days | C$6.10 | C$4.45 – C$8.35 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
5.12% Surge in One Day
Medexus Pharmaceuticals Inc's stock rose by 5.12% in the last trading session, reflecting investor confidence following the announcement of strong fiscal results.
Bull case
The strong fiscal year 2026 results highlight Medexus's ability to keep up momentum and drive revenue growth, especially with GRAFAPEX gaining traction in the market. The recent license agreement for UM171 Cell Therapy also opens new revenue opportunities.
Bear case
Despite the positive performance, Medexus still faces challenges, like a lack of profitability and the need to establish a stronger market presence for its products. Investors should remain cautious about the company's long-term financial health.
Strong Fiscal Year Results
Medexus recently announced its fiscal year 2026 results, showcasing solid performance and ongoing growth in its product line. The success of GRAFAPEX has been a key driver, indicating strong market demand and effective commercialization strategies.
Strategic Partnerships and Growth
The company's recent license and supply agreement for UM171 Cell Therapy in Canada shows its commitment to expanding its portfolio. These strategic partnerships are vital for Medexus as they aim to enhance their market position and drive future revenue.
Market Sentiment and Investor Confidence
The positive movement in Medexus's stock reflects increasing investor confidence in the company's direction. As Medexus navigates the complexities of the pharmaceutical industry, its recent successes could lead to sustained growth and profitability.
Advertisement
Wealth Awesome Newsroom
The Wealth Awesome Newsroom delivers timely Canadian market updates, earnings, dividends, and stock movers for DIY investors. Coverage is reviewed against public filings and market data feeds.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
